The promise of Regulus Therapeutics Inc. 's microRNA add-on therapy RG-101 for hepatitis C to reduce duration of treatment to four weeks was diminished by an FDA clinical hold, but the biotech reve
South Korea's GtreeBNT Co. Ltd. is preparing or proceeding with late stage clinical trials in the US for its drug development pipeline, while exploring licensing out opportunities to validate its busi
IN VITRO DIAGNOSTICS Mergers & Acquisitions Abbott Laboratories Inc. Alere Inc. Abbott Laboratories Inc. is paying $56 per share (a 50% premium) or $5.8bn to acquire fellow public firm Alere Inc
IN VITRO DIAGNOSTICS Mergers & Acquisitions Abbott Laboratories Inc. Alere Inc. Abbott Laboratories Inc. is paying $56 per share (a 50% premium) or $5.8bn to acquire fellow public firm Alere Inc